BioNTech (BNTX) Stocks Pops on Big Sales Beat

Shares of BioNTech (NASDAQ: BNTX) are up around 1.5% in preopen Monday after the biotech company reported better-than-expected Q1 EPS and revenue.

The German biotechnology company reported a Q1 EPS of €14.24, up from €4.39 in the year-ago period and the consensus estimates of €8.62. Revenue came in at €6.37, topping the estimated €4.01 billion.

In the first quarter, BioNTech generated €1.16 billion in direct coronavirus vaccine sales in Germany and Turkey, in addition to €603.2 million in sales of products made by BioNTech for its partners.

Commercial revenues in the first quarter included €4.59 billion gross profit share in territories allocated between Pfizer, BioNTech and Fosun Pharma.

For the full fiscal year, BNTX expects capital expenditure in the range of €450 million to €550 million, while analysts were looking for €390.3 million. Coronavirus vaccine revenue is expected to be in the range of EU13 billion to EU17 billion, compared to the consensus projection of EU15.62 billion.

By Senad Karaahmetovic

You May Also Be Interested In

• US big banks Q2 earnings preview: strong prints on tap amid market, economic strength
• BioNTech (BNTX) PT Lowered to $119 at Morgan Stanley
• Ericsson (ERIC) Tops Q2 EPS by 3c